Our products are available in 60 countriesClick here to learn more
Our activities incorporate all areas of the pharmaceutical value chainClick here to learn more
Innovation is one of the pillars of our strategy. We devote approximately EUR 50 million to research and development.Click here to learn more
Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October. In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products. Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.
We have commemorated World Cancer Day.
In parallel to our mission, we serve people with all our knowledge and skills, so that they can live a long and healthy life. As Diamond Sponsor of the comprehensive nationwide health tests program, Egis Pharmaceuticals is devotedly engaged in the improvement of the Hungarian healthcare. Furthermore, thanks to the company’s commitment, hundreds of residents as well as the employees of the municipality of the 10th district (or Kőbánya) are offered free health tests within the ‘Egis Health and Prevention Days’.
On the occasion of the national holiday, Dr. István Hodász, CEO of Egis was granted the award ‘For the Hungarian Economy’ by Deputy Prime Minister and Minister of Finance Mihály Varga. The award is the most prestigious recognition to be given by the Minister of Finance on ministerial level for outstanding excellence and contribution to the Hungarian economy.
Egis tied as the most popular employer for science students and young graduates and early-stage professionals, found a new study analysing the preferences of young employees and graduates in Hungary.
The performance of the Hungarian pharmaceutical industry in the last ‘peaceful year’ before the coronavirus epidemic was reviewed in a comprehensive analysis by Nézőpont Institute on behalf of 16 pharmaceutical companies of the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ).
As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők.
Disinfection plays an important role in reducing the risk of infection. As a responsible company, Egis supports the safe operation of pharmacies in the second wave of the coronavirus pandemic as well.
Egis ’products are available in 60 countries. Our portfolio consists of 617 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.Learn more about our products